$COCH

Envoy Medical (COCH) settled litigation with Atlas Merchant Capital, dismissing all claims without payment. The case involved alleged redemption rights from their 2023 business combination. The agreement ends further legal proceedings.

Envoy Medical, Inc. (COCH) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On October 6, 2026, Envoy Medical, Inc., a Delaware corporation (the “Company”), entered into a Dismissal Agreement (the “Dismissal Agreement”) regarding litigation in the Delaware Court of Chancery (the “Litigation”) with Atlas Merchant Capital SPAC Fund

Lake Street initiated coverage on Envoy Medical (COCH) with a buy rating and $2.50 price target, citing potential upside of 270%. The company's Acclaim cochlear implant is in development, with pivotal trial data meeting expectations. Envoy reported Q2 2026 revenue of $51,000 and a net loss of $7.3 million. Other analysts maintain buy ratings with varying price targets.

Envoy Medical, Inc. (COCH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers On August 24, 2026, Envoy Medical, Inc. (the “Company”) appointed Robert Potashnick to serve as the Company’s Chief Accounting Officer and Vice President of Finance. M

Analysts updated price targets for several companies. Baird raised Ross Stores (ROST) target to $270, Parsons (PSN) to $57, and Deere (DE) to $640. BTIG cut Walmart (WMT) target to $140. HSBC raised Ternium (TX) target to $55. Rothschild & Co increased Equifax (EFX) target to $235. Other changes include Envoy Medical (COCH), MDxHealth (MDXH), Hometrust Bancshares (HTB), and Haemonetics (HAE).

Envoy Medical, Inc. (COCH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Envoy Medical Reports Second Quarter 2026 Results and Achieves Key Regulatory and Clinical Milestones Submitted First Module of Modular PMA Application to FDA Subsequent to Quarter End, the Company Reported Positive 12-Month Stage 1 Data Showing Continued Improvement

Envoy Medical (NASDAQ: COCH) said it has passed the three-month visit milestone for all 56 patients in its pivotal trial of the investigational fully implanted Acclaim cochlear implant. The company continues collecting safety and study measures for a planned FDA PMA submission. It expects six-month enrollment by late 2026 and 12-month study data by April 2027.

Envoy Medical (NASDAQ: COCH) reported positive 12-month interim results from Stage 1 of its pivotal trial for the investigational fully implanted Acclaim cochlear implant. In 10 participants, mean CNC word recognition rose to 53.2% from a 15.2% baseline. No protocol-defined serious adverse events were reported. Stage 2 is fully enrolled.

Cochin Shipyard shares fell 4.1% to ₹1,445.1 on Tuesday after India’s government announced an Offer for Sale of up to 5.04% of its stake at a floor price of ₹1,400, a >7% discount to the prior day. The OFS supply weighed on the stock; government holds 67.92%.

India’s Department of Investment and Public Asset Management said the government will sell up to 5.04% of its stake in Cochin Shipyard via an offer for sale. The base sale is 2.52% with an option for another 2.52% if oversubscribed. The floor price is 1,400 rupees/share, a >7% discount to the last close. Non-retail opens Tuesday; retail Wednesday.